Global Anti-Epileptic
Drugs Market, by Generation (First Generation, Second Generation, and Third
Generation), by Route of Administration (Oral and Intravenous), by Distribution
Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and
by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa) is estimated to be valued at US$
7,155.6 million in 2019 and is estimated to exhibit a CAGR of 6.6%over
the forecast period (2019-2027), as highlighted in a new report published by
Coherent Market Insights.
The number of available
anti-epilepsy drugs has doubled over the past several decades as the benefits
of anti-epilepsy medicines are higher than the possible side-effects from the
medicine. Moreover, the U.S. FDA has approved 28 drugs for the treatment of
epilepsy and many generic versions of anti-epileptic drugs have been launched
by manufacturers.
The U.S. FDA has only approved
anticonvulsant medications for seizure disorders in children. Moreover, the
currently available newer anti-seizure drugs have simple pharmacokinetics and
more limited effects on liver metabolism, thus driving growth of the
anti-epileptic drugs market for pediatrics.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1701
The increasing improvements in
efficacy of medications of treating epilepsy is expected to fuel growth of the
anti-epileptic drugs market over the forecast period. For instance, newer drugs
have exhibited better efficacy, owing to better pharmacokinetic profiles and
fewer drug interactions than the classic first-generation drugs. For instance,
the third-generation drugs developed by UCB’s Keppra (levetiracetam) and
GlaxoSmithKline’s (GSK’s) Lamictal (lamotrigine) transitioned rapidly to the
‘Blockbuster’ status and have replaced the older gold standards in most of the
markets as first-line treatments. According to the Epilepsy Foundation report
of 2013, the newer third-generation AEDs have provided complete control over
seizures to over half of the patients with epilepsy and reduced the number of
seizures in another 20-30% of patients, thereby proving the success rate of the
newer AEDs.
Browse 35 Market Data Tables and
30 Figures spread through 201 Pages and in-depth TOC on "Global
Anti-epileptic Drugs Market, by Generation (First Generation, Second
Generation, and Third Generation), by Route of Administration (Oral and
Intravenous), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies,
and Online Pharmacies), and by Region (North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/antiepileptic-drugs-market-1701
Key Takeaways of the Global
Anti-epileptic Drugs Market:
The global anti-epileptic drug
market expected to exhibit a CAGR of 6.6% over the forecast period (2019-2027),
owing to emergence of novel efficacious anti-epileptic drugs
Among generation, third
generation segment is expected to account for major revenue share by 2027,
owing to rising demand for third generation anti-epileptic drugs, which is
rapidly outpacing the first generation and second generation anti-epileptic
drugs, mostly for the treatment of children and adolescents.
Major players operating in the
global anti-epileptic drug market include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson
Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A.,
Sumitomo Dainippon Pharma Co., Ltd., Mylan N.V., Bausch Health Companies Inc.,
and UCB S.A.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1701
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment